Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2
News
News | 07 April 2026

Lupin secures global Great Place To Work certification for 2026-27

Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development

News
News | 07 April 2026

Vedanta’s community healthcare programmes reach 30 lakh people, FY26 spend crosses Rs 50 crore

The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management

News
News | 06 April 2026

Red Nucleus acquires Bridge Medical Consulting with advisory support from VERTICES PARTNERS

As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm

News
News | 06 April 2026

Samsung Biologics lands first US manufacturing facility with GSK acquisition

Samsung Biologics will continue supplying products previously manufactured at the site to GSK

News
News | 05 April 2026

Cupid deposits Rs. 82.88 crore for strategic stake in Baazar Style Retail

The deal gives Cupid immediate access to Style Baazar’s fast-growing network of over 260 stores

News
News | 05 April 2026

Senores makes bold US push with new federal-focused JV

Company leadership is framing the move as transformational.

News
News | 04 April 2026

BASF Pharma Solutions announces up to 20% price hike on excipients and APIs

The company said the increase—up to 20%—takes effect immediately, or as current contracts allow

News
News | 04 April 2026

PHARMEXCIL Chintan Shivir in Hyderabad charts roadmap to scale India’s pharma exports

Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26

News
News | 03 April 2026

ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses

Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology

News
News | 03 April 2026

Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer

Its a major breakthrough for women’s ovarian cancer care in Europe

News
News | 03 April 2026

Cardinal Health boosts production of cutting-edge cancer therapy ingredient

Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.

News
News | 02 April 2026

Alembic Pharmaceuticals partners with Enthral.ai for learning and training management of its 9000+ learners

Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows

News
News | 02 April 2026

Glenmark Pharmaceuticals accelerates U.S. strategy with direct RYALTRIS distribution

This marks a meaningful step in the company's continued expansion in the region

News
News | 02 April 2026

D2C nutrition brand BeastLife raises Rs 20 crore at Rs 320 crore valuation from GVFL and Equentis

The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years

News
News | 02 April 2026

FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions

The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants

News
News | 02 April 2026

Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients

Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina

News
News | 02 April 2026

Lupin completes acquisition of VISUfarma

The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe

News
News | 02 April 2026

Emcure Pharma reduces Poviztra starting dose price by 55% in India

The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country

News
News | 02 April 2026

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio

Startup

Digitization